“…This practice has led to the true risks being underestimated, and (in our opinion) to an over-reliance on chemoprophylaxis to compensate for high-risk ascent profiles (see Table 2 of our article, adapted from Wilderness Medical Society guidelines [1,4] ) rather than risk reduction through profile adjustment. [5] This increasing use of and/or reliance on chemoprophylaxis has also been described elsewhere, such as in Himalayan trekkers. [6] Furthermore, while there is good evidence that acetazolamide undoubtedly hastens acclimatisation (numbers needed to treat in the range of 3 -8, depending on circumstance [6][7][8] ), it cannot compensate for excessively rapid ascent.…”